However, it's not going to rocket out of the gate like pharmaceutical products are known to do. In what Zomedica CEO Robert Cohen called a “momentous day” (and I agree), the company recorded the first veterinarian sale of Truforma. And, that’s not even the end of the bull run. That marked the stock’s 52-week high. 8 Stocks to Buy for March But, no matter what kind of “bet” these investors are making, the important part is whether it’s one where the odds are in their favor. With shares today trading for a substantial premium to what could be its “best case scenario,” downside risk looks to be vastly ahead of the potential for additional gains. What do I mean? That implies an eventual share price well into the double-digits. Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. ANN ARBOR, Mich., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced the appointment of Robert Cohen as Chief Executive Officer effective January 1, 2021. Reconsider ZOM stock as a buy if that happens. Given the vast size of the pet diagnostics market, it’s not difficult to envision Zomedica achieving many more milestones in 2021. Louis Navellier and the InvestorPlace research staff did a terrific job of summarizing the Truforma diagnostic platform, which is designed to identify thyroid and adrenal issues in dogs and cats: “Instead of shipping a blood test to a third-party lab, veterinarians and technicians can use the product to run the tests themselves… That makes the diagnostic process quicker and cheaper — two factors that will definitely appeal to worried pet owners.” In what Zomedica CEO Robert Cohen called a “momentous day” (and I agree), the company recorded the first veterinarian sale of Truforma. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. In addition, the global veterinary immunodiagnostic market has been predicted to expand at a CAGR of 9.6% and reach $2.1 billion by the year 2022. In 2018, the company thrived on other exchanges, but it fell by 2019 (down 91.61 percent over a … ©2021  Zomedica Corp. and Zomedica Inc. All rights reserved. Zomedica Announces First Quarter 2021 Financial Results. May 12, 2021 4:43 PM ET Zomedica Corp. (ZOM) By: Akanksha Bakshi, SA News Editor 3 Comments Zomedica Pharmaceuticals (NYSE: ZOM ) : Q1 GAAP EPS of -$0.04. Jaguar Health (JAGX) shed 17% after it upsized by $15.3 million a financing program launched in … On Feb 8, a Seeking Alpha contributor broke down possible growth scenarios for Zomedica. ANN ARBOR, Mich, May 12, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three months ended March 31, 2021.Amounts, unless specified otherwise, are expressed in U.S. dollars and … Truforma’s previously disclosed commercialization target date had been set for March 30. On the date of publication, Thomas Niel did not (either directly or indirectly) hold any positions in the securities mentioned in this article. Wall Street isn't expecting Zomedica to top $20 million in sales until 2023. Zomedica and the Zomedica logo are registered trademarks of Zomedica Inc.TRUFORMA is a registered trademark of Zomedica Corp. Privacy Notice           Terms of Use          Forward Looking Statements. Or is the opportunity to make money on Zomedica stock largely over? But, for now, hold off buying. Measuring Risk/Return With ZOM Stock is No Easy Task Those buying Zomedica today are as much making a bet on the future of Truforma, as they are making a bet that Truforma quickly becomes a widely used veterinary diagnostic product. But, back-of-the-envelope calculations like this bolster the case that it’s share price is testament to its “meme stock status,” rather than its strong chances of dominating this market. Adding to the heat, Zomedica recently announced the first commercial sale of its new product, the Truforma diagnostic platform. Do this now. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn’t matter if you have $500 in savings or $5 million. Here are the relevant stats, courtesy of Zomedia: 67% of households (nearly 85 million homes) in the U.S. have at least one pet. For traders seeking fast action, ZOM stock hasn’t disappointed them in 2021 so far. Bottom Line: Zomedica Has a Lot to Prove, So Wait for Lower Prices It’s safe to say I hold a more skeptical view of this stock. Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. In the meantime, the company still needs to execute the commercialization of Truforma. By Zomedica’s own stock sales, it sold off two-thirds of the equity of the company for just $50 million. On the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article. To be blunt, taking 9 years to get sales up to $53 million isn’t going to cut it. Press Release reported on … Announces Full Exercise of Over-Allotment Option by Underwriter Zomedica Corp. The company’s veterinary diagnostic product, Truforma, may be a big hit once it’s commercialized. Zomedica first announced its plans to commercialize Truforma back on Nov. 13. Discover new investment ideas by accessing unbiased, in-depth investment research, NYSE American - Nasdaq Real Time Price. Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Do this now. Zomedica Corp. , a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported... Zomedica Announces First Quarter 2021 Financial Results Research: Stocks: News … Therefore, if you had invested $1,000 in ZOM stock at the beginning of the period, you would have nearly $38,600 at the end of it. A Major Milestone By now, you should be convinced that Zomedica’s addressable market is vast and worth pursuing, but without a significant product launch, it would be awfully difficult for Zomedica to capitalize on this opportunity. Announces Year End 2020 Financial Results, Zomedica Corp. Upcoming Webinar Latest News More News View RACE-Approved Webinars For instance, Zomedica was a clinical-stage company until the first commercial sale of its Truforma diagnostics system for companion animals in mid-March. #1 Play to Profit from Biden's Presidency The post All Bets are Off Whether Zomedica Stock Grows Into Its Valuation appeared first on InvestorPlace. Zomedica isn’t an exception. Thus, the commercialization appears to be moving forward ahead of schedule, which isn’t a bad thing at all for Zomedica. The Bottom Line It’s all about the baby steps – first one veterinarian sale of Truforma, and later (hopefully) many more sales. But, to justify its valuation, Zomedica will need to capture a pretty large share of this market, which is set to be worth $2.8 billion per year in sales by 2024.InvestorPlace - Stock Market News, Stock Advice & Trading Tips So, weighing potential versus valuation, what’s the best move for investors looking to enter the stock today? We expect Zomedica ZOM investors to focus on the outlook for the company’s first commercial product, scheduled to be launched on Mar 30, 2021, when it … H.W. Shares Trade Well Above Their “Best Case Scenario” As I wrote previously, ZOM stock is not only richly-priced on its current fundamentals. For those who don’t know, IDEXX sports a market capitalization of nearly $45 billion. If that’s the case, then you’re going to want to learn more about Zomedica’s flagship product and the recently announced milestone related to it.InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’ll certainly delve into those topics, along with the growth potential of the broader pet diagnostics market. Rationality is coming back to the pricing of Zomedica (NYSEAMERICAN:ZOM) stock. The shares have pulled back since early February and trade today around $1.50. Zomedica announced on March 16 the first official sale of its Truforma platform to a veterinarian in the U.S. Zomedica’s first customer was an animal hospital in New York City. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post Pounce on This Pullback in the Zomedica Share Price appeared first on InvestorPlace. So, perhaps you’ll be able to buy ZOM stock at a bargain price. Investors in veterinary testing and pharmaceutical company Zomedica (NYSEAMERICAN:ZOM) stock have had their share of ups and downs this year. Announces $25.0 Million Bought Deal Offering of Common Shares, Zomedica Signs TRUFORMA™ Distribution Agreement With Miller Veterinary Supply. Also worth noting is that the company’s earnings per share on a trailing 12-month basis is -5 cents. Cash and cash equivalents of $276.6M. Subscribe to Yahoo Finance Plus to view Fair Value for ZOM. The ZOM stock buyers took a breather for several weeks, but then catapulted the share price up to $2.91 on Feb. 8. I’ll admit, it’s not exactly the most talked-about topic in the financial media. In company news, PPD (PPD) was up 6.6% with Thermo Fisher Scientific (TMO) adding 3.7% after the latter struck a deal to buy PPD for $47.50 per share, or $17.4 billion in cash. If you’re concerned about buying the stock at its peak price, no need to worry. © 2021 Verizon Media. Zomedica Corp. (AMEX:ZOM) went down by -7.59% from its latest closing price compared to the recent 1-year high of $2.91. That is to say, the potential for shares to gain vastly exceeds the risk shares fall back towards penny stock levels. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. But, with today’s valuation pricing in a lot of what this company could be potentially worth by decade’s end, it’s hard to argue ZOM stock has room to double once again.